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Postoperative nausea and vomiting (PONV) occur in 30–50% of patients undergoing general anesthesia and in 70–80% of high
PONV risk patients. In this study, we investigated the efficacy of fosaprepitant, a neurokinin-1 (NK1) receptor antagonist, compared
to ondansetron, a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, in moderate to high PONV risk patients
from our previous randomized controlled trials. Patients (171 patients from 4 pooled studies) with the Apfel simplified score ≥
2 and undergoing general anesthesia were randomly allocated to receive intravenous fosaprepitant 150mg (NK1 group, 𝑛 = 82)
and intravenous ondansetron 4mg (ONS group, 𝑛 = 89) before induction of anesthesia. Incidence of vomiting was significantly
lower in the NK1 group compared to the ONS group 0–2, 0–24, and 0–48 hours after surgery (2 versus 17%, 2 versus 28%, and 2
versus 29%, resp.). However, no significant differences in PONV, complete response, rescue antiemetic use, and nausea score were
observed between groups 0–48 hours after surgery. In moderate to high PONV risk patients, fosaprepitant decreased the incidence
of vomiting and was superior to ondansetron in preventing postoperative vomiting 0–48 hours after surgery.
1. Introduction
Postoperative nausea and vomiting (PONV) are distress-
ing and serious adverse effects of anesthesia and surgery.
PONV is experienced by 30–50% of patients undergoing
general anesthesia and up to 70–80% of high PONV risk
patients (female patients, nonsmokers, patients with history
of PONV and/or motion sickness, and receiving opioids
postoperatively [1–4]). In the “Consensus guidelines for
the management of postoperative nausea and vomiting”
[4], use of antiemetics for PONV prophylaxis is recom-
mended in moderate to high risk patients. Additionally, in
patients receiving prophylactic treatment for PONV, such as
ondansetron, a selective 5-hydroxytryptamine type 3 (5-HT3)
receptor antagonist, PONV, occurs in up to 30–40% of the
patients during the first postoperative day [2, 5, 6]. In addition
to patient distress and discomfort, PONV increases the risk
of venous thrombus or pulmonary embolism, interferes with
physical therapy, and prolongs hospital stay [7–9]. Therefore,
more effective therapies for preventing PONV are required,
particularly in high risk patients.
Fosaprepitant is a water-soluble phosphorylated prodrug
of aprepitant, a highly selective neurokinin-1 (NK1) recep-
tor antagonist, and is rapidly transformed into aprepitant
when administered intravenously [10]. Aprepitant blocks
NK1 receptors and demonstrates antiemetic efficacy and a
long half-life, with two large trials finding aprepitant advanta-
geous in preventing PONV, compared to ondansetron [11–13].
Fosaprepitant is used for managing chemotherapy-induced
nausea and vomiting (CINV) and was reported to have
superior, longer-lasting effect in preventing CINV, compared
to other antiemetics [14].
Recently, we reported that fosaprepitant was more effec-
tive than ondansetron in preventing vomiting 0–24 and
0–48 h after surgery [15–17]. In this study, we collected data
from our previous studies and evaluated the efficacy of
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fosaprepitant in preventing PONV compared to ondansetron
in moderate to high PONV risk patients.
2. Methods
This analysis was based on data from four identically
designed, double-blind, randomized, controlled studies.
These studies were approved by the Human Research
Ethics Committee of the University of Tokushima (Tokush-
ima, Japan) and registered in a clinical trials database
(UMIN000008621, 000012999, 000007613, and 000018532).
Written informed consent was obtained from all patients, and
the studies were conducted in accordance with the principles
outlined in the Declaration of Helsinki.
Patients (aged 20–80 years) with the American Society of
Anesthesiologists (ASA) physical status of I–III and undergo-
ing general anesthesia were enrolled in the studies. They all
had Apfel simplified score for PONV ≥ 2, which includes 4
factors: female sex, history of PONV and/or motion sickness,
nonsmoker smoking status, and postoperative opioids use.
Patients with 0-1, 2, and 3-4 factors are considered to be
at low, moderate, and high risk for PONV, respectively [2].
Exclusion criteria were ASA physical status of IV, neural
diseases, abnormal liver and/or renal function, and use of
other antiemetics. Patient data recorded included gender,
history of PONV and motion sickness, and smoking status.
Patients were randomized and allocated to groups using
Quickcalcs software (Graph-Pad Inc., La Jolla, CA, USA).
To ensure investigator blinding randomization schedule was
generated by a statisticianwhowas not involved in the clinical
study. On the day of surgery, patients were randomized to
the NK1 group, which received intravenous fosaprepitant
(150mg) and the ONS group, which received intravenous
ondansetron (4mg). Antiemetics were infused over 30min
by anesthesiologists before induction of anesthesia, following
approved administration protocols.
Anesthesia was induced with remifentanil 0.3–0.5𝜇g/kg/
min, propofol 1-2mg/kg, and rocuronium 0.8mg/kg to facil-
itate endotracheal intubation. Anesthesia was maintained
with propofol (target controlled infusion: 2–4𝜇g/ml) or
volatile anesthetics (sevoflurane 1-2% or desflurane 3-4%)
in oxygen with air mixture, remifentanil, and fentanyl.
Incremental doses of rocuronium were used as necessary
for muscle relaxation, which was reversed by sugammadex
2mg/kg at the end of surgery. A rescue antiemetic (10mg
metoclopramide) and/or analgesic were administered on
patient request.
The incidence of nausea and vomiting, complete response
rate (no vomiting and no rescue antiemetic use), rescue
antiemetic use, and severity of nausea were evaluated by
blinded observers 2, 24, and 48 hours after surgery. The
severity of nausea was estimated using the nausea score (0,
absence of nausea; 1–3 mild, moderate, and severe nausea,
resp.). Scores were evaluated by blinded observers, who
determined the highest scores in each surveyed period and
all adverse events during the first 48 hours after surgery were
recorded.
Statistical analyses were performed using Statistical Pack-
age for Social Sciences (SPSS) software (version 22, SPSS
Table 1: Patient demographics.
NK1 group ONS group
Patients 𝑛 = 82 𝑛 = 89
Age, years 57 ± 14 56 ± 13
Height, cm 154 ± 8 155 ± 6
Weight, kg 57 ± 11 56 ± 10
ASA PS I/II/III 23/58/1 27/61/1
PONV risk factors
Nonsmoker (𝑛) 80 88
History of motion sickness (𝑛) 26 22
Women (𝑛) 82 89
Postoperative opioids, 𝜇g 470 ± 449 443 ± 451
Duration of anesthesia, min 269 ± 124 280 ± 138
Duration of surgery, min 209 ± 113 219 ± 129
Anesthetics; remifentanil, mg 3.4 ± 2.4 3.2 ± 3.2
Blood loss, ml 321 ± 488 251 ± 360
Fluid volume, ml 2245 ±
1312
2127±1101
Data are presented as means ± SD (or range) or number of patients; NK1
group, i.v. fosaprepitant; ONS group, i.v. ondansetron; PONV, postoperative
nausea and vomiting; ASA PS, American Society of Anesthesiologists
physical status.
INC., Chicago, IL, USA). Data are expressed as means ±
standard deviations. 𝑃 values < 0.05 were considered statis-
tically significant without any adjustment for multiplicity of
testing. 𝑇-test and 𝜒2 test were used for analyzing patient
demographics, cumulative incidence of vomiting at each
time point, incidence of nausea, rescue antiemetic use, and
complete response (no vomiting and no rescue) 0–2, 0–24,
and 0–48 hours after surgery.TheMann–Whitney𝑈 test was
used to analyze nausea score at these time points.
3. Results
This study included 171 female patients with the Apfel
simplified score ≥ 2 (82 in the NK1 group and 89 in the ONS
group). No significant differences in patient demographics,
risk factors for PONV, duration of anesthesia and surgery,
blood loss, and fluid volume were observed between the
groups (Table 1).
There was no significant difference in the percentage of
patients with no vomiting and no rescue (complete response)
at 0–2 hours (78 versus 80%, resp.; 𝑃 = 0.852), 0–24 hours (71
versus 67%, resp.; 𝑃 = 0.741), and 0–48 hours (71 versus 67%,
resp.; 𝑃 = 0.741) after surgery. However, the incidence of
vomiting was significantly lower in the NK1 group compared
to the ONS group at 0–2 hours (2 versus 17%, resp.; 𝑃 =
0.0016), 0–24 hours (2 versus 28%, resp.; 𝑃 < 0.0001), and
0–48 hours (2 versus 29%, resp.; 𝑃 < 0.0001) after surgery
(Table 2). Where rates of vomiting were adjusted for use of
rescue antiemetic, both groupswere similar in terms of rescue
antiemetic use for the 0–48 h interval. The rescue antiemetic
was administered 10mg metoclopramide when the patients
required postoperative rescue antiemetic. No statistically
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Table 2: Postoperative parameters.
NK1 group, 𝑛 = 82 ONS group, 𝑛 = 89 𝑃 value
0–2 hours
PONV 34 (41%) 25 (28%) 0.077
Complete response 64 (78%) 71 (80%) 0.852
Vomiting 2 (2%)∗ 15 (17%) 0.0016
Rescue antiemetic use 18 13 0.238
0–24 hours
PONV 45 (55%) 44 (49%) 0.647
Complete response 58 (71%) 60 (67%) 0.741
Vomiting 2 (2%)∗ 25 (28%) <0.0001
Rescue antiemetic use 30 26 0.331
0–48 hours
PONV 45 (55%) 47 (53%) 0.878
Complete response 58 (71%) 60 (67%) 0.741
Vomiting 2 (2%)∗ 26 (29%) <0.0001
Rescue antiemetic use 30 29 0.631
Data are presented as number of patients (percentile); NK1 group, i.v. fosaprepitant; ONS group, i.v. ondansetron; PONV, postoperative nausea and vomiting.
∗
𝑃 <0.05 compared to ONS group.






Severity of nausea (0/1/2/3) 48/15/10/9 65/6/4/14
2–24 hours
Severity of nausea (0/1/2/3) 62/10/6/4 57/10/10/12
24–48 hours
Severity of nausea (0/1/2/3) 76/5/1/0 77/6/2/4
Data are presented as number of patients or median (interquartile range);
NK1 group, i.v. fosaprepitant; ONS group, i.v. ondansetron; severity of
nausea: 0 = absence of nausea, 1 = mild nausea, 2 = moderate nausea, and
3 = severe nausea.
significant differences in PONV, rescue antiemetic use, and
nausea score were observed between the groups for any
analyzed period (Tables 2 and 3).
4. Discussion
This study indicated that fosaprepitant is superior to
ondansetron in preventing vomiting 0–2, 0–24, and 0–48
hours after surgery in moderate to high PONV risk patients.
No significant differences were observed between fosaprepi-
tant and ondansetron in incidence of PONV, complete
response rate, use of rescue antiemetics, and severity of
nausea.
Several neurotransmitter receptor systems including
dopaminergic, cholinergic, histaminergic, serotonergic (5HT-
2 and 5HT-3), and NK1 systems are associated with nausea
and vomiting [18]. 5HT-3 receptor antagonists and NK1
receptor antagonists were shown to be effective in preventing
CINV. A corticosteroid and a 5HT-3 receptor antagonist are
often combined for preventing CINV. Recently, NK1 recep-
tor antagonists, aprepitant and fosaprepitant, have become
available and their use has improved the management of
CINV [19]. In the 2016 update of MASCC/ESMO consensus
guidelines, for prophylaxis of acute and delayed nausea and
vomiting induced by chemotherapy, a combination of a 5-
HT3 receptor antagonist, dexamethasone, and aNK1 receptor
antagonist is recommended [20]. NK1 receptor antagonists
are expected to reduce the incidence of CINV.
NK1 receptor antagonist aprepitant was shown to be
effective in preventing PONV.Diemunsch et al. [12] suggested
that aprepitant was significantly superior to ondansetron in
preventing vomiting. Gan et al. [11] showed that aprepitant
was as effective in reducing nausea as ondansetron and more
effective in preventing vomiting during the first 24 and 48
hours after surgery. Moreover, analysis of data from two
clinical trials [13] indicated that aprepitant was superior to
ondansetron in preventing PONV.
In this study, we used fosaprepitant, a prodrug of aprepi-
tant. Fosaprepitant is converted to aprepitant within 30 min-
utes of intravenous administration and blocks NK1 receptors.
A dose of 115mg of fosaprepitant was reported equivalent to
125mg of aprepitant [10], with intravenous administration
of 150mg of fosaprepitant showing the same efficacy as a
3-day oral aprepitant treatment (125/80/80mg) [21]. In our
previous studies [15–17], we demonstrated the efficacy of
fosaprepitant in preventing PONV in patients undergoing
general anesthesia compared to ondansetron. This study
enrolledmoderate to high PONV risk patients and confirmed
fosaprepitant efficacy compared to ondansetron. Improved
efficacy of fosaprepitant in preventing postoperative vomiting
may be attributed to its long half-life.
For moderate to high PONV risk patients, multimodal
prevention approaches can reduce the risk of PONV. Con-
sensus guidelines for managing postoperative nausea and
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vomiting [4] recommend an antiemetic combination of
dexamethasone (4mg) and ondansetron (4mg). Considering
the superior antiemetic effect of fosaprepitant compared to
ondansetron in this study, a combination of dexamethasone
and fosaprepitant (instead of ondansetron) may be more
effective. Moreover, long half-life of fosaprepitant suggests
that a single administration of fosaprepitant may be equiv-
alent or more effective than a combination dexamethasone-
ondansetron treatment in preventing PONV. Further evalua-
tion of clinical characteristics of fosaprepitant in combination
with other antiemetics for PONV prevention is planned.
Certain limitations should be noted. Fosaprepitant has a
much longer half-life than ondansetron and, consequently,
longer duration of activity, which may account for improved
prevention of vomiting. Additionally, as antiemetics are
expected to be more effective when administered towards the
end of surgery compared to during induction of anesthesia,
timing of drug administration could have affected our results.
Moreover, fosaprepitant treatment is relatively expensive,
costing US$ 122.5 in Japan. However, as use of antiemetics
can reduce complications associated with PONV, preventing
prolonged hospital stays, total medical costs may decrease.
As we did not evaluate long-term outcomes in this study,
it remains unclear whether reduction of postoperative vom-
iting by fosaprepitant improves postoperative outcomes or
provides additional benefits for patients. Further studies
are required to evaluate the contribution of fosaprepitant
treatment to postoperative outcomes.
5. Conclusions
This study demonstrated that NK1 receptor antagonist
fosaprepitant was superior to 5HT-3 receptor antagonist
ondansetron in preventing vomiting 0–2, 0–24, and 0–48
hours after surgery in moderate to high PONV risk patients.
However, no significant differences were observed between
fosaprepitant and ondansetron in PONV incidence, complete
response, use of rescue antiemetics, and nausea severity at any
period analyzed.
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